Lilly buys AtaiBeckley·$3.8bnOtsuka buys Transcend·$1.2bnAbbVie buys Gilgamesh·$1.2bnatai buys Beckley Psytech·terms undisclosedAbbVie takes an option on Gilgamesh·$2bnLilly buys AtaiBeckley·$3.8bnOtsuka buys Transcend·$1.2bnAbbVie buys Gilgamesh·$1.2bnatai buys Beckley Psytech·terms undisclosedAbbVie takes an option on Gilgamesh·$2bnLilly buys AtaiBeckley·$3.8bnOtsuka buys Transcend·$1.2bnAbbVie buys Gilgamesh·$1.2bnatai buys Beckley Psytech·terms undisclosedAbbVie takes an option on Gilgamesh·$2bn
Next issueIssue 16 · Tue 29 Sep 

Assets

psilocybin (investigator-led; PEX010)

Slagelse Hospital

Molecule class
psilocybin
Mechanism
not_applicable
Phase
Phase 2 authorised
Indication
treatment-resistant anorexia nervosa
Sponsor geography
DK
Next catalyst
None recorded.
IP status
not_applicable

euclinicaltrials.euregistryverified 2026-09-08

Registered trials

In the briefing

Issues tagged SLAGELSE, the owner of this asset.